Amphilix AG is developing small molecular chimeras utilizing a unique linker platform based on Spirochem AG synthetic technology.
About Us
The platform enables efficient linking of advanced lead compounds and fine-tuning of molecular properties.
This results in drug candidates with superior benefits for patients over those of Standard-of-care treatments and new possibilities in addressing unmet medical needs.
Amphilix’ initial project designs dimeric scaffolds for use in the fields of oncology, inflammation and ophthalmology and will be followed by further drug mechanisms and compounds to build a portfolio of differentiating first-in-class or best-in-class products.
Amphilix AG was founded in 2020 and operates in the Basel area of Switzerland, a hub of pharmaceutical and biotechnology research and development.
Our Team
Guido Koch
Co-founder and CEO
PhD Medicinal chemist ex-Director of Global Discovery Chemistry at Novartis. Since 2017, Chief Operating Officer at Topadur Pharma AG, Schlieren, Switzerland
Kevin McAllister
Co-founder and Chairman
PhD, MBA, Pharmacologist, ex-Executive Director in Neuroscience & Principal Medical Scientific Expert, Neuroscience Development Franchise at Novartis. Currently Managing Director of Neurenable GmbH and Chief Scientific Officer at SOM Biotech SL, Barcelona, Spain
Thomas Fessard
Co-founder and Board Member
PhD Medicinal chemist co-founder and CEO of SpiroChem AG since 2011. Previously, Thomas was Head of Drug Discovery and Chemistry at Lipideon Biotechnology AG
Peter Harboe-Schmidt
Co-founder
MSc, MBA, co-founder & Chairman of SpiroChem AG and CFO at Cutiss AG. Co-founder of several other life science companies. Previously Head of Business Planning at Amgen Europe. Peter has also worked as Headcoach for Innosuisse
